Corient Private Wealth’s Cytokinetics CYTK Stock Holding History

Corient Private Wealth’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$440K	Sell	5,161 -1,987	-28%	-$143K	﹤0.01%	2315
2026 Q1	$470K	Buy	7,148 +104	+1%	+$6.61K	﹤0.01%	2064
2025 Q4	$447K	Buy	7,044 +2,231	+46%	+$139K	﹤0.01%	1924
2025 Q3	$265K	Buy	+4,813	New	+$198K	﹤0.01%	2196
2025 Q2	–	Sell	-6,416	Closed	-$258K	–	2460
2025 Q1	$258K	Buy	+6,416	New	+$295K	﹤0.01%	1936
2024 Q2	–	Sell	-3,165	Closed	-$222K	–	2332
2024 Q1	$222K	Sell	3,165 -1,766	-36%	-$137K	﹤0.01%	2051
2023 Q4	$412K	Buy	+4,931	New	+$179K	﹤0.01%	1709

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's CYTK Position: Q2 2026 in Review

Corient Private Wealth reduced its Cytokinetics (CYTK) stake by 28% in Q2 2026, selling an estimated $143K and leaving 5,161 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #2315.

Corient Private Wealth first reported a position in CYTK in Q4 2023 and has held it in 7 quarters since. The position peaked at $470K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Corient Private Wealth held 5,161 shares of Cytokinetics worth $440K as of Q2 2026.
Corient Private Wealth sold 1,987 Cytokinetics shares in Q2 2026, an estimated $143K.
Cytokinetics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2315 holding.
Corient Private Wealth first reported a position in Cytokinetics in Q4 2023 and has held it in 7 quarters since.
Corient Private Wealth's Cytokinetics position peaked at $470K in Q1 2026.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.